Cargando…
Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
OBJECTIVES: Iron is an essential element for cell proliferation and growth processes. We have reported that deferasirox (DFX), an oral iron chelator, showed antiproliferative activity against pancreatic cancer cells. This study aimed to elucidate the effects of combination of gemcitabine (GEM), stan...
Autores principales: | Shinoda, Shuhei, Kaino, Seiji, Amano, Shogo, Harima, Hirofumi, Matsumoto, Toshihiko, Fujisawa, Koichi, Takami, Taro, Yamamoto, Naoki, Yamasaki, Takahiro, Sakaida, Isao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033369/ https://www.ncbi.nlm.nih.gov/pubmed/29983871 http://dx.doi.org/10.18632/oncotarget.25421 |
Ejemplares similares
-
Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
por: Amano, Shogo, et al.
Publicado: (2020) -
Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
por: Amano, Shogo, et al.
Publicado: (2023) -
Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo
por: Harima, Hirofumi, et al.
Publicado: (2016) -
Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
por: Yamamoto, Naoki, et al.
Publicado: (2016) -
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)